Artiva Biotherapeutics, Inc.
ARTV
$2.47
$0.020.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.88% | 2.08% | -27.79% | -16.38% | -206.37% |
| Total Depreciation and Amortization | -2.07% | 3.98% | 2.73% | -1.18% | 6.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -48.67% | -37.54% | 172.74% | -28.08% | 49.83% |
| Change in Net Operating Assets | -110.34% | 43,085.71% | 99.77% | -177.46% | 95.43% |
| Cash from Operations | -26.17% | 15.16% | 9.29% | -41.32% | 0.68% |
| Capital Expenditure | 33.33% | 79.31% | -2,477.78% | 97.17% | -255.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.31% | -7,299.78% | -81.50% | 582.28% | -547.13% |
| Cash from Investing | 99.26% | -9,783.32% | -86.21% | 466.64% | -441.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 13.16% | 51.28% | -- | -- | -- |
| Issuance of Common Stock | -99.99% | 756,777.27% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.23% | -66.86% | -- | -- | -95.89% |
| Cash from Financing | -100.02% | 10,240.59% | -- | -- | -95.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.32% | 255.05% | -163.05% | 57.16% | -201.57% |